Bio-Techne Rebrands B-MoGen Biotechnologies As Part Of The R&D Systems Product Portfolio

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its B-MoGen Biotechnologies portfolio to R&D Systems on September 21, 2020. This change includes the retirement of the B-MoGen website, with all products and services now accessible through R&D Systems' site. President Dave Eansor highlighted that this consolidation aims to enhance service offerings for cell and gene therapy customers, providing value-added services alongside high-quality products. More details on the TcBuster gene transfer system can be found on their new site.

Positive

• Consolidation of B-MoGen into R&D Systems enhances service offerings.
• Streamlined access to legacy products through a single platform.

Negative

• None.

MINNEAPOLIS, Sept. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary transposon-transposase gene transfer system, TcBuster™, will be rebranded as R&D Systems. As part of the rebranding, the B-MoGen Biotechnologies website will be retired. Service details and purchasing options will be maintained through the R&D Systems website. Currently all legacy B-MoGen products and services can be purchased through R&D Systems.

Dave Eansor, President of Bio-Techne's Protein Sciences Segment, commented, "We are excited to consolidate the B-MoGen portfolio within R&D Systems' extended offering of discovery-to-clinic cell and gene therapy solutions. Cell and gene therapy customers are looking for value-added services to complement the high-quality products that they purchase from R&D systems. With this consolidation, we can meet the needs of our customers in new and dynamic ways."

More information on the TcBuster and other legacy B-MoGen Biotechnologies services can be found at www.rndsystems.com/products/genome-engineering

About Bio-Techne Corporation (NASDAQ: TECH)

Contact:	David Clair, Senior Director, Corporate Development
	david.clair@bio-techne.com
	612-656-4416

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-rebrands-b-mogen-biotechnologies-as-part-of-the-rd-systems-product-portfolio-301133853.html

SOURCE Bio-Techne Corporation

FAQ

What is the recent rebranding by Bio-Techne related to stock symbol TECH?

Bio-Techne rebranded its B-MoGen Biotechnologies portfolio as R&D Systems on September 21, 2020.

How does the rebranding impact Bio-Techne's services?

The rebranding consolidates services under R&D Systems, aiming to provide enhanced value for cell and gene therapy customers.

Where can I find information about the TcBuster gene transfer system?

Information on the TcBuster gene transfer system is available on the R&D Systems website.